We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    The efficacy, safety and tolerability of probiotics on the mood and cognition of depressed patients:
Previous Study | Return to List | Next Study

The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02838043
Recruitment Status : Completed
First Posted : July 20, 2016
Last Update Posted : June 14, 2019
Sponsor:
Collaborators:
Lallemand Health Solutions
McMaster University
Information provided by (Responsible Party):
Dr. Roumen Milev, Queen's University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will be an 8-week open-label pilot study examining subjective and objective changes in mood, anxiety, cognition, and sleep before and after the introduction of a probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum in 10 treatment-naïve participants diagnosed with major depressive disorder (MDD). In order to examine the full composition of the micro biome, the investigators will also be collecting and analyzing fecal samples as well as blood samples to examine changes in plasma levels of inflammatory markers, 5-HT, and tryptophan in order to look at possible underlying mechanisms of any changes seen.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Depression Depressive Symptoms Dietary Supplement: Probio'Stick Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients
Study Start Date : August 2016
Actual Primary Completion Date : May 2018
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Participant
All participants will be experimental and receive Probio'Stick.
 Dietary Supplement: Probio'Stick
A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Mood [ Time Frame: 8 weeks ]
    Mood will be assessed with the Montgomery-Asberg Depression Rating Scale (MADRS) with a cut-off score of 12 indicating remission.


Secondary Outcome Measures :
  1. Anxiety [ Time Frame: 8 weeks ]
    Anxiety will be assessed with the Generalized Anxiety Disorder Scale (GAD-7).

  2. Cognition [ Time Frame: 8 weeks ]
    Cognition will be assess with the Digit Symbol Substitution Test (DSST).

  3. Sleep [ Time Frame: 8 weeks ]
    Sleep will be assessed objectively using a polysomnogram to look at changes electrophysiological sleep architecture after 8 weeks of treatment.

  4. Plasma [ Time Frame: 8 weeks ]
    Plasma will be analyzed to look at levels of inflammatory markers to see whether there is a decrease after 8 weeks of treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of Major Depressive Disorder (MDD) by Mini International Neuropsychiatric Interview (MINI)
  2. Current depressive episode with a MADRS score of ≥ 20
  3. Males and females between ages 18 and 65
  4. Able to understand and comply with the requirements of the study
  5. Provision of written informed consent

Exclusion Criteria:

  1. Use of any antidepressant drug
  2. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a 1-month washout period)
  3. Use of any sleep medication in the past 4 weeks (may be eligible to participate after a 1-month washout period)
  4. Milk, yeast, or soy allergy
  5. History of alcohol or substance abuse in the past 6 months
  6. Daily use of probiotic product in the past 2 weeks (may be eligible to participate after a 2-week washout period)
  7. Use of any type of laxative
  8. Consumption of products fortified in probiotics
  9. Severely suicidal
  10. Experiencing psychosis or bipolar episode
  11. History of epilepsy or uncontrolled seizures
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02838043


Locations
Layout table for location information
Canada, Ontario
Queen's University
Kingston, Ontario, Canada, K7L 3N6
Providence Care - Mental Health Services
Kingston, Ontario, Canada, K7L 4X3
Sponsors and Collaborators
Queen's University
Lallemand Health Solutions
McMaster University
Investigators
Layout table for investigator information
Principal Investigator: Roumen Milev, PhD, MD Queen's University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dr. Roumen Milev, Psychiatrist, Queen's University
ClinicalTrials.gov Identifier: NCT02838043    
Other Study ID Numbers: 6016312
First Posted: July 20, 2016    Key Record Dates
Last Update Posted: June 14, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant data will not be shared.
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Depressive Disorder, Major
 Behavioral Symptoms
Mood Disorders
Mental Disorders